Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise and Omico's Precision Oncology Screening Platform (PrOSPeCT) to better match patients with suitable cancer studies, expanding access to targeted therapies. This effort aims to optimize study center selection and speed up patient enrollment, enhancing the development of personalized cancer treatments. The partnership also supports the use of genomic data and real-world evidence to advance cancer drug development globally.
Fortrea Holdings and Omico's partnership on biomarker-based cancer drug development coincides with a health sector market where 47 of 150 US stocks rose and 103 fell on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 24, 2026 00:21 WIB: TNGX (Tango Therapeutics Inc.) traded at USD 24.25 with a 1-day change of -13.16% and 100% buy order activity; WGS (GeneDx Holdings Corp) at USD 61.15, down 8.92%, with 54% buy orders; and INO (Inovio Pharmaceuticals Inc) rose 8.48% to USD 0.91, with 27% buy orders and a typical hold time of 43 days.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Greg Abel highlighted that every one percentage point increase in the profit margin of BNSF Railway translates to approximately $230 million in additional cash flow for Berkshire Hathaway. This underscores the significant impact BNSF's operational ef...
